Citations

Showing 10 of 108119 citations.

Comment: Introducing Neuromodulation in 2035
Jones, Lyell K., Gross, Robert A., Jones, Lyell K., Gross, Robert A.

Mayo Clinic

Neurology | January 10, 2022 | Volume: 98 | Issue: 2 | Pages: 64-64

10.1212/wnl.0000000000013064 | PMID 35263272 Get It

Abnormal Iron and Lipid Metabolism Mediated Ferroptosis in Kidney Diseases and Its Therapeutic Potential
Zhang, Xiaoqin , Li, Xiaogang

Mayo Clinic

Metabolites | January 10, 2022 | Volume: 12 | Issue: 1 | Pages: 58

10.3390/metabo12010058 | PMID 35050181 Get It

Ferroptosis is a newly identified form of regulated cell death driven by iron-dependent phospholipid peroxidation and oxidative stress. Ferroptosis has distinct biological and morphology characteristics, such as shrunken mitochondria when compared to other known regulated cell deaths. The regulation of ferroptosis includes different molecular mechanisms and multiple cellular metabolic pathways, including glutathione/glutathione peroxidase 4(GPX4) signaling pathways, which are involved in the amino acid metabolism and the activation of GPX4; iron metabolic signaling pathways, which are involved in the regulation of iron import/export and the storage/release of intracellular iron through iron-regulatory proteins (IRPs), and lipid metabolic signaling pathways, which are involved in the metabolism of unsaturated fatty acids in cell membranes. Ferroptosis plays an essential role in the pathology of various kidneys diseases, including acute kidney injury (AKI), chronic kidney disease (CKD), autosomal dominant polycystic kidney disease (ADPKD), and renal cell carcinoma (RCC). Targeting ferroptosis with its inducers/initiators and inhibitors can modulate the progression of kidney diseases in animal models. In this review, we discuss the characteristics of ferroptosis and the ferroptosis-based mechanisms, highlighting the potential role of the main ferroptosis-associated metabolic pathways in the treatment and prevention of various kidney diseases.
A Structure-based Design Approach for Generating High Affinity BRD4 D1-Selective Chemical Probes
Cui, Huarui , Divakaran, Anand , Hoell, Zachariah J. , Ellingson, Mikael O., Scholtz, Cole R. , Zahid, Huda , Johnson, Jorden A., Griffith, Elizabeth C., Gee, Clifford T. , Lee, Amani L. , Khanal, Shalil , Shi, Ke , Aihara, Hideki , Shah, Vijay H. , Lee, Richard , Lee, Richard E , Harki, Daniel A , Pomerantz, William C K , Harki, Daniel A. , Pomerantz, William C. K. , Lee, Amani

Mayo Clinic

Journal of Medicinal Chemistry | January 10, 2022 | Volume: 65 | Issue: 3 | Pages: 2342-2360

10.1021/acs.jmedchem.1c01779 | PMID 35007061 Get It

Telogator: a method for reporting chromosome-specific telomere lengths from long reads
Stephens, Zachary, Ferrer, Alejandro, Boardman, Lisa, Kocher, Jean‐Pierre , Kocher, Jean-Pierre A , Ferrer, Alejandro , Boardman, Lisa, Iyer, Ravishankar K.

Mayo Clinic

Bioinformatics | January 10, 2022 | Volume: 38 | Issue: 7 | Pages: 1788-1793

10.1093/bioinformatics/btac005 | PMID 35022670 Get It

Abstract Motivation Telomeres are the repetitive sequences found at the ends of eukaryotic chromosomes and are often thought of as a ‘biological clock,’ with their average length shortening during division in most cells. In addition to their association with senescence, abnormal telomere lengths are well known to be associated with multiple cancers, short telomere syndromes and as risk factors for a broad range of diseases. While a majority of methods for measuring telomere length will report average lengths across all chromosomes, it is known that aberrations in specific chromosome arms are biomarkers for certain diseases. Due to their repetitive nature, characterizing telomeres at this resolution is prohibitive for short read sequencing approaches, and is challenging still even with longer reads. Results We present Telogator: a method for reporting chromosome-specific telomere length from long read sequencing data. We demonstrate Telogator’s sensitivity in detecting chromosome-specific telomere length in simulated data across a range of read lengths and error rates. Telogator is then applied to 10 germline samples, yielding a high correlation with short read methods in reporting average telomere length. In addition, we investigate common subtelomere rearrangements and identify the minimum read length required to anchor telomere/subtelomere boundaries in samples with these haplotypes. Availability and implementation Telogator is written in Python3 and is available at github.com/zstephens/telogator. Supplementary information Supplementary data are available at Bioinformatics online.
A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia
Mascarenhas, John , Kosiorek, Heidi E., Prchal, Josef T. , Rambaldi, Alessandro, Berenzon, Dmitriy, Yacoub, Abdulraheem , Harrison, Claire N., McMullin, Mary Frances , Vannucchi, Alessandro M. , Ewing, Joanne, O'Connell, Casey L., Mead, Adam J. , Winton, Elliott F., Leibowitz, D , Arcasoy, Murat O., Kessler, Craig M., Catchatourian, Rosalind, Rondelli, Damiano, Silver, Richard T., Bacigalupo, Andrea, Nagler, Arnon, Kremyanskaya, Marina, Sandy, Lonette, Salama, Mohamad E., Najfeld, Vesna, Tripodi, Joseph , Farnoud, Noushin , Penson, Alexander , Weinberg, Rona Singer , Barbui, Tiziano , Marchioli, Roberto, Tognoni, Gianni, Rampal, Raajit K., Mesa, Ruben A., Dueck, Amylou C. , Hoffman, Ronald, Rambaldi, Alessandro , Najfeld, Vesna , Kiladjian, Jean-Jacques , Mead, Adam J , Leibowitz, David S , De Stefano, Valerio , Levine, Max F , Arango Ossa, Juan E , McGovern, Erin , Tripodi, Joseph , Farnoud, Noushin , Penson, Alexander V , Weinberg, Rona Singer , Price, Leah , Goldberg, Judith D , Barbui, Tiziano , Dueck, A. C. , Vannucchi, Alessandro M , Mascarenhas, John , Rambaldi, Alessandro , McMullin, Mary Frances , Najfeld, Vesna , Kosiorek, Heidi E., Prchal, Josef T. , Berenzon, Dmitriy, Yacoub, Abdulraheem , Harrison, Claire N., Ewing, Joanne, O'Connell, Casey L., Winton, Elliott F., Arcasoy, Murat O., Kessler, Craig M., Catchatourian, Rosalind, Rondelli, Damiano, Silver, Richard T., Bacigalupo, Andrea, Nagler, Arnon, Kremyanskaya, Marina, Sandy, Lonette, Salama, Mohamad E., Marchioli, Roberto, Tognoni, Gianni, Rampal, Raajit K., Mesa, Ruben A., Hoffman, Ronald

Mayo Clinic

Blood | January 10, 2022 | Volume: 139 | Issue: 19 | Pages: 2931-2941

10.1182/blood.2021012743 | PMID 35007321 Get It

Abstract The goal of therapy for patients with essential thrombocythemia (ET) and polycythemia vera (PV) is to reduce thrombotic events by normalizing blood counts. Hydroxyurea (HU) and interferon-α (IFN-α) are the most frequently used cytoreductive options for patients with ET and PV at high risk for vascular complications. Myeloproliferative Disorders Research Consortium 112 was an investigator-initiated, phase 3 trial comparing HU to pegylated IFN-α (PEG) in treatment-naïve, high-risk patients with ET/PV. The primary endpoint was complete response (CR) rate at 12 months. A total of 168 patients were treated for a median of 81.0 weeks. CR for HU was 37% and 35% for PEG (P = .80) at 12 months. At 24 to 36 months, CR was 20% to 17% for HU and 29% to 33% for PEG. PEG led to a greater reduction in JAK2V617F at 24 months, but histopathologic responses were more frequent with HU. Thrombotic events and disease progression were infrequent in both arms, whereas grade 3/4 adverse events were more frequent with PEG (46% vs 28%). At 12 months of treatment, there was no significant difference in CR rates between HU and PEG. This study indicates that PEG and HU are both effective treatments for PV and ET. With longer treatment, PEG was more effective in normalizing blood counts and reducing driver mutation burden, whereas HU produced more histopathologic responses. Despite these differences, both agents did not differ in limiting thrombotic events and disease progression in high-risk patients with ET/PV. This trial was registered at www.clinicaltrials.gov as #NCT01259856.
Sirolimus-Based Immunosuppression Is Associated with Decreased Incidence of Post-Transplant Lymphoproliferative Disorder after Heart Transplantation: A Double-Center Study
Asleh, Rabea , Vucicevic, D., Petterson, Tanya M. , Kremers, Walter K. , Pereira, Naveen L. , Daly, Richard C. , Edwards, Brooks S., Steidley, D. Eric , Scott, Robert L. , Kushwaha, Sudhir S. , Asleh, Rabea , Kremers, Walter K

Mayo Clinic

Journal of Clinical Medicine | January 10, 2022 | Volume: 11 | Issue: 2 | Pages: 322

10.3390/jcm11020322 | PMID 35054016 Get It

Mammalian target of rapamycin (mTOR) inhibitors have been shown to reduce proliferation of lymphoid cells; thus, their use for immunosuppression after heart transplantation (HT) may reduce post-transplant lymphoproliferative disorder (PTLD) risk. This study sought to investigate whether the sirolimus (SRL)-based immunosuppression regimen is associated with a decreased risk of PTLD compared with the calcineurin inhibitor (CNI)-based regimen in HT recipients. We retrospectively analyzed 590 patients who received HTs at two large institutions between 1 June 1988 and 31 December 2014. Cox proportional-hazard modeling was used to examine the association between type of primary immunosuppression and PTLD after adjustment for potential confounders, including Epstein–Barr virus (EBV) status, type of induction therapy, and rejection. Conversion from CNI to SRL as primary immunosuppression occurred in 249 patients (42.2%). During a median follow-up of 6.3 years, 30 patients developed PTLD (5.1%). In a univariate analysis, EBV mismatch was strongly associated with increased risk of PTLD (HR 10.0, 95% CI: 3.8–26.6; p < 0.001), and conversion to SRL was found to be protective against development of PTLD (HR 0.19, 95% CI: 0.04–0.80; p = 0.02). In a multivariable model and after adjusting for EBV mismatch, conversion to SRL remained protective against risk of PTLD compared with continued CNI use (HR 0.12, 95% CI: 0.03–0.55; p = 0.006). In conclusion, SRL-based immunosuppression is associated with lower incidence of PTLD after HT. These findings provide evidence of a benefit from conversion to SRL as maintenance therapy for mitigating the risk of PTLD, particularly among patients at high PTLD risk.
Reevaluation of the Layered Anatomy of the Forehead: Introducing the Subfrontalis Fascia and the Retrofrontalis Fat Compartments
Ingallina, Fabio, Frank, Konstantin, Mardini, Samir, Gavril, Diana L., Hernandez, Claudia A., Benslimane, Fahd, Gotkin, Robert H., Davidovic, Kristina, Moellhoff, Nicholas, Cotofana, Sebastian, Ingallina, Fabio, Frank, Konstantin, Mardini, Samir, Gavril, Diana L., Hernandez, Claudia A., Benslimane, Fahd, Gotkin, Robert H., Davidovic, Kristina, Moellhoff, Nicholas, Cotofana, Sebastian

Mayo Clinic

Plastic & Reconstructive Surgery | January 10, 2022 | Volume: 149 | Issue: 3 | Pages: 587-595

10.1097/prs.0000000000008826 | PMID 35006205 Get It

Background: Novel imaging methods have provided new insights into the layered anatomy of the forehead. This study seeks to critically reevaluate the layered anatomy of the forehead by using ultrasound imaging and cadaveric dissection to provide an accurate anatomical description that can be used to guide safer surgical and minimally invasive frontal procedures. Methods: This study used ultrasound imaging in a sample of 20 volunteers (12 female and eight male volunteers; aged 35.25 ± 4.2 years; body mass index, 24.28 ± 3.5 kg/m2) and cadaveric dissections of 16 body donors (12 female and four male body donors; aged 72.76 ± 9.5 years) to reevaluate the layered anatomy of the forehead. Layer-by-layer dissections and ultrasound-based measurements of the frontal structures guided conclusions. Results: The following layered arrangement was identified: layer 1, skin; layer 2, superficial fatty layer; layer 3, suprafrontalis fascia; layer 4, orbicularis oculi and frontalis muscle (same plane); layer 5, a homogenous layer of fat [preseptal fat (in the upper eyelid), retro-orbicularis fat (deep to the orbicularis oculi muscle), and retro-frontalis fat (deep to the frontalis muscle); layer 6, subfrontalis fascia; layer 7, preperiosteal fat within the prefrontal space in the lower forehead and deep compartments in the upper forehead; and layer 8, periosteum. Conclusions: The results of this study add to the current understanding of the layered arrangement of the forehead. The combination of ultrasound imaging and cadaveric dissections provided evidence for a continuous fatty layer deep to the frontalis muscle.
Reliving #ASH21: The Historic 63rd ASH Annual Meeting
Gangat, Naseema

Mayo Clinic

The Hematologist | January 10, 2022 | Volume: 19 | Issue: 1 | Pages: No page available

10.1182/hem.v19.1.2022114 Get It

Anticoagulants for Hospitalized Patients With COVID-19: The Year of Randomized Controlled Trials
Houghton, Damon E.

Mayo Clinic

The Hematologist | January 10, 2022 | Volume: 19 | Issue: 1 | Pages: No page available

10.1182/hem.v19.1.202211 Get It

Histologic and proteomic remodeling of the pulmonary veins and arteries in a porcine model of chronic pulmonary venous hypertension
Fayyaz, Ahmed, Sabbah, Michael S. , Dasari, Surendra , DuBrock, Hilary M. , Charlesworth, M. Cristine , Borlaug, Barry A. , Jenkins, Sarah M. , Edwards, William D. , Redfield, Margaret M. , Fayyaz, Ahmed U., DuBrock, Hilary M , Charlesworth, M. Cristine , Borlaug, Barry A , Griffiths, Leigh G. , Wang, Ying

Mayo Clinic

Cardiovascular Research | January 10, 2022 | Volume: 119 | Issue: 1 | Pages: 268-282

10.1093/cvr/cvac005 | PMID 35022664 Get It

Abstract Aims In heart failure (HF), pulmonary venous hypertension (PVH) produces pulmonary hypertension (PH) with remodeling of pulmonary veins (PV) and arteries (PA). In a porcine PVH model, we performed proteomic-based bioinformatics to investigate unique pathophysiologic mechanisms mediating PA and PV remodeling. Methods and results Large PV were banded (PVH, n = 10) or not (Sham, n = 9) in piglets. At sacrifice, PV and PA were perfusion labelled for vessel-specific histology and proteomics. The PA and PV were separately sampled with laser-capture micro-dissection for mass spectrometry. Pulmonary vascular resistance [Wood Units; 8.6 (95% confidence interval: 6.3, 12.3) vs. 2.0 (1.7, 2.3)] and PA [19.9 (standard error of mean, 1.1) vs. 10.3 (1.1)] and PV [14.2 (1.2) vs. 7.6 (1.1)] wall thickness/external diameter (%) were increased in PVH (P &lt; 0.05 for all). Similar numbers of proteins were identified in PA (2093) and PV (2085) with 94% overlap, but biological processes differed. There were more differentially expressed proteins (287 vs. 161), altered canonical pathways (17 vs. 3), and predicted upstream regulators (PUSR; 22 vs. 6) in PV than PA. In PA and PV, bioinformatics indicated activation of the integrated stress response and mammalian target of rapamycin signalling with dysregulated growth. In PV, there was also activation of Rho/Rho-kinase signalling with decreased actin cytoskeletal signalling and altered tight and adherens junctions, ephrin B, and caveolae-mediated endocytosis signalling; all indicating disrupted endothelial barrier function. Indeed, protein biomarkers and the top PUSR in PV (transforming growth factor-beta) suggested endothelial to mesenchymal transition in PV. Findings were similar in human autopsy specimens. Conclusion These findings provide new therapeutic targets to oppose pulmonary vascular remodeling in HF-related PH.